2 results
Approved WMOCompleted
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…
Approved WMOPending
Primary Objectives- To investigate the impact of dose reduction of 18F-FDG on image quality of PET-MRII in patients with melanoma. Secondary Objectives- To determine the maximum reduction of radiation dose for 18F-FDG PET-MRI as compared to…